Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.
Location: France, Ile-de-France, Paris
Total raised: $17.42M
Investors 1
| Date | Name | Website |
| - | Bioqube Ve... | bioqubeven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.10.2022 | - | $17.42M | - |
Mentions in press and media 4
| Date | Title | Description |
| 12.10.2022 | TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP FIRST-IN-CLASS IMMUNE CHECKPOINT AGONISTS | Paris, France, September 15, 2022 – Tridek-One SAS (the ‘Company’), a leading biotech start- up specialized in the research and development of CD31 agonists to restore the immune balance, today announces it has closed a €16 million ($16.1M)... |
| 16.09.2022 | Tridek-One Closes €16M Funding | Tridek-One, a Paris, France-based biotech startup specialized in the research and development of CD31 agonists to restore the immune balance, raised €16M in funding. The round was led by Pureos Bioventures with participation from Bpifrance,... |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
| - | Tridek-One | “The Future of immunomodulation” |